Investment Partners Ltd. OH ADV decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 14.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,439 shares of the company’s stock after selling 2,523 shares during the period. Johnson & Johnson accounts for approximately 1.7% of Investment Partners Ltd. OH ADV’s investment portfolio, making the stock its 16th largest position. Investment Partners Ltd. OH ADV’s holdings in Johnson & Johnson were worth $1,798,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Lenox Wealth Advisors Inc. boosted its position in Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock valued at $108,000 after buying an additional 6 shares during the last quarter. Thomas J. Herzfeld Advisors Inc. purchased a new position in Johnson & Johnson during the fourth quarter valued at $117,000. Taylor Wealth Management Partners boosted its position in Johnson & Johnson by 19.8% in the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after buying an additional 250 shares during the last quarter. Foundation Resource Management Inc. purchased a new position in Johnson & Johnson during the first quarter valued at $204,000. Finally, Arbor Investment Advisors LLC purchased a new position in Johnson & Johnson during the first quarter valued at $215,000. Institutional investors and hedge funds own 65.98% of the company’s stock.

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.925% during midday trading on Friday, reaching $131.145. The company’s stock had a trading volume of 987,005 shares. The firm has a market capitalization of $351.99 billion, a P/E ratio of 22.190 and a beta of 0.78. The stock has a 50-day moving average of $132.91 and a 200 day moving average of $128.25. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. The business had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company’s revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.74 earnings per share. Equities research analysts predict that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be given a $0.84 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.54%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 56.76%.

TRADEMARK VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/01/johnson-johnson-jnj-position-reduced-by-investment-partners-ltd-oh-adv.html.

Several equities analysts have recently weighed in on the company. UBS AG reissued a “buy” rating and set a $136.00 price target on shares of Johnson & Johnson in a report on Monday, May 15th. Cowen and Company set a $147.00 price target on Johnson & Johnson and gave the company a “buy” rating in a report on Thursday, August 24th. J P Morgan Chase & Co increased their price target on Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a report on Wednesday, August 16th. Jefferies Group LLC set a $145.00 price target on Johnson & Johnson and gave the company a “hold” rating in a report on Tuesday, August 15th. Finally, Wells Fargo & Company reissued a “market perform” rating and set a $135.00 price target (up from $132.00) on shares of Johnson & Johnson in a report on Thursday, July 6th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $133.91.

In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares in the company, valued at $30,993,466.96. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.